Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
- Description:
Neurotoxin, widely used to produce the 6-OHDA Parkinson’s disease model
Purity:>98%
ABT 724 trihydrochloride (HB1883)
Description:Potent dopamine D4 receptor partial agonist
Purity:>99%
Amisulpride (HB1879)
Description:Potent, selective dopamine D2 and D3 receptor antagonist. Atypical antipsychotic.
Purity:>98%
Bromocriptine mesylate (HB1813)
Description:Potent, selective D2-like receptor agonist
Purity:>98%
- Description:
Fluorescent D1 dopamine receptor antagonist
Clozapine (HB1607)
Description:Prototypic, atypical antipsychotic, binds to both serotonin and dopamine receptors
Purity:>99%
- Description:
Water soluble prototypic, atypical antipsychotic. Binds to both serotonin and dopamine receptors.
Purity:>98%
Dihydroergocristine mesylate (HB1611)
Description:5-HT antagonist. Also partial agonist at adrenergic and dopaminergic receptors.
Purity:>98%
L-DOPA methyl ester hydrochloride (HB5354)
Description:Water soluble L-DOPA derivative
Purity:>98%